Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant
Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant

NCT05899829

CompletedPhase 1

Sponsor: Bellus Health Inc. - a GSK company

Conditions: Cough, Healthy

Interventions: Camlipixant, Rabeprazole, Rifampin

Countries: Canada

This is a phase 1, 2-part, open-label, fixed-sequence study evaluating the effect of rifampin (part 1) and rabeprazole (part 2) on the pharmacokinetics of a single dose of camlipixant (BLU-5937) 50 mg tablet in healthy participants under fasting conditions.

Eligibility overview

Sex: ALL

Age: 18 Years to 55 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Healthy males or non-pregnant, non-lactating healthy females

Exclusion Criteria:

* History of clinically significant history of neurological, endocrine, cardiovascular, respiratory, hematological, immunological, psychiatric, gastrointestinal, renal, hepatic, and metabolic disorder, as judged by the investigator.
Locations (1)
  • Québec, Quebec, Canada